A study on lipoprotein-a and PAI-1 in women with polycystic ovary syndrome
-
Ashok Kumar Shah
and
Amrendra Kumar Shah
Abstract
Objectives
PCOS is the most common endocrinological disorder amongst women of reproductive age. The consequences of PCOS extend beyond the reproductive axis and may lead to the development of metabolic syndrome leading to a high risk for hypertension and cardiovascular disease. Therefore, a more comprehensive evaluation of biochemical markers that reflect the cardiovascular risk is required for further understanding of pathophysiologic mechanisms, diagnosis and management.
Methods
In this case-control study, women diagnosed with PCOS (n=100) in the age group (18–35 years) years were taken as cases and age matched healthy controls (n=100) were enrolled. Estimations of fasting plasma Glucose, serum total cholesterol (TC), triglycerides (TG) and High-density lipoprotein (HDL) concentrations were assayed while Low-density lipoprotein (LDL) was calculated by using Fredrickson Friedwald’s formula. Serum Lipoprotein-a (Lp-a) was estimated using ELISA (Enzyme Linked Immunosorbent Assay). The quantitative data were expressed as Mean ± Standard Deviation (SD). Unpaired Student’s t-test was used to compare the values (PCOS vs Controls) and Pearson’s correlation coefficient was used to elucidate the relationship between the variables.
Results
FBS and all lipid parameters were significantly increased in PCOS patients compared to control subjects. On the other hand, HDL-C was significantly decreased as compared to the control subjects. The hormones TSH, LH, FSH, PRL and LH/FSH ratio were significantly increased in PCOS patients compared to control subjects. Lipoprotein-a and PAI-1 was significantly increased in PCOS patients compared to the control subjects. Upon bivariate correlation analysis, Lp(a) had significant correlations with PAI-1 (r=0.35, p=0.000), WHR (r=0.25, p=0.000), LDL (r=0.52, p=0.000) and TSH (r=0.24, p=0.000). While the correlations with FBS (r=−0.008, p=0.91) and LH/FSH ratio (r=−0.004, p=0.95) were statistically insignificant.
Conclusions
The evaluation of serum biomarkers such as Lp-a, PAI-1 and lipid profile routinely in PCOS patients may have diagnostic role in the early detection of metabolic abnormalities and endocrine derangements and timely management of comorbid Diabetes and Cardiovascular disease in PCOS females.
-
Research funding: No funding sources.
-
Competing interests: None declared.
References
1. Hoffman, BL, Schorge, JO, Halvorson, LM, Bradshaw, KD, Cunningham, FG. Polycystic ovarian syndrome and hyperandrogenism: Williams gynecology, 2nd ed New York City, USA: McGraw Hill Medical; 2012:460 p.Search in Google Scholar
2. Gazvani, MR, Hamilton, M, Kingsland, CR, Templeton, A. Polycystic ovarian disease: a misleading label? Lancet 2000;355:411–2.10.1016/S0140-6736(05)74039-3Search in Google Scholar
3. Ferriman, D, Gallwey, JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440–7.10.1210/jcem-21-11-1440Search in Google Scholar
4. Vgontzas, AN, Legro, RS, Bixler, EO, Grayev, A, Kales, A, Chrousos, GP. Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of insulin resistance. J Clin Endocrinol Metab 2001;86:517–20.10.1210/jc.86.2.517Search in Google Scholar
5. Fogel, RB, Malhotra, A, Pillar, G, Pittman, SD, Dunaif, A, White, DP. Increased prevalence of obstructive sleep apnea syndrome in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 2001;86:1175–80.10.1210/jc.86.3.1175Search in Google Scholar
6. Rocco, A, Falaschi, P, Perrone, G, Pancheri, P, Rosa, M, Zichella, L. Psychoneuroendocrine aspects of polycystic ovary syndrome. J Psychosom Obstet Gynecol 1991;12:169–79.10.3109/01674829109077999Search in Google Scholar
7. Laggari, V, Diareme, S, Christogiorgos, S, Deligeoroglou, E, Christopoulos, P, Tsiantis, J, et al.. Anxiety and depression in adolescents with polycystic ovary syndrome and Mayer-Rokitansky-Küster-Hauser syndrome. J Psychosom Obstet Gynecol 2009;30:83–8.10.1080/01674820802546204Search in Google Scholar
8. Franks, S. Polycystic ovary syndrome. N Engl J Med 1995;333:853–61.10.1056/NEJM199509283331307Search in Google Scholar
9. Azziz, R, Woods, KS, Reyna, R, Key, TJ, Knochenhauer, ES. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745–9.10.1210/jc.2003-032046Search in Google Scholar
10. Gill, H, Tiwari, P, Dabadghao, P. Prevalence of polycystic ovary syndrome in young women from North India: a community-based study. Indian J Endocrinol Metab 2012;16:S389–92.10.4103/2230-8210.104104Search in Google Scholar
11. Spandana, JC, Shetty, PK. A study on the clinical, biochemical and hormonal profile of polycystic ovary syndrome patients attending tertiary care hospital. Int J Reprod Contracept Obstet and Gynecol 2017;6:1986–92.10.18203/2320-1770.ijrcog20171963Search in Google Scholar
12. Balen, A. Pathogenesis of polycystic ovary syndrome–the enigma unravels? Lancet 1999;354:966–7.10.1016/S0140-6736(99)00218-4Search in Google Scholar
13. Legro, RS, Kunselman, AR, Dunaiff, A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 2001;111:607–13.10.1016/S0002-9343(01)00948-2Search in Google Scholar
14. Essah, PA, Nestler, JE. Metabolic syndrome in women with polycystic ovary syndrome. Fertil Steril 2006;86:S18.10.1016/j.fertnstert.2006.04.013Search in Google Scholar PubMed
15. Essah, PA, Nestler, JE. The metabolic syndrome in polycystic ovary syndrome. J Endocrinol Invest 2006;29:270–80.10.1007/BF03345554Search in Google Scholar PubMed
16. Kalra, A, Nair, S, Rai, L. Association of obesity and insulin resistance with dyslipidemia in Indian women with polycystic ovarian syndrome. Indian J Med Sci 2006;60:447–53.10.4103/0019-5359.27971Search in Google Scholar
17. Diamanti-Kandarakis, E. Role of obesity and adiposity in polycystic ovary syndrome. Int J Obes 2007;31:S8–13.10.1038/sj.ijo.0803730Search in Google Scholar PubMed
18. Diamanti-Kandarakis, E, Papavassiliou, AG, Kandarakis, SA, Chrousos, GP. Pathophysiology and types of dyslipidemia in PCOS. Trends Endocrinol Metabol 2007;18:280–5.10.1016/j.tem.2007.07.004Search in Google Scholar PubMed
19. Farrell, K, Antoni, MH. Insulin resistance, obesity, inflammation, and depression in polycystic ovary syndrome: biobehavioral mechanisms and interventions. Fertil Steril 2010;94:1565–74.10.1016/j.fertnstert.2010.03.081Search in Google Scholar PubMed PubMed Central
20. Magnotti, M, Futterweit, W. Obesity and the polycystic ovary syndrome. Med Clin 2007;91:1151–68.10.1016/j.mcna.2007.06.010Search in Google Scholar PubMed
21. Pinon, P, Kaski, JC. Inflammation, atherosclerosis, and cardiovascular disease risk: PAPP-A, Lp-PLA2, and cystatin C. New insights or redundant information? Rev Esp Cardiol 2006;59:247–58.10.1157/13086082Search in Google Scholar
22. Scicchitano, P, Dentamaro, I, Carbonara, R, Bulzis, G, Dachille, A, Caputo, P, et al.. Cardiovascular risk in women with PCOS. Int J Endocrinol Metab 2012;10:611–8.10.5812/ijem.4020Search in Google Scholar PubMed PubMed Central
23. Lippi, G, Guddi, G. Lipoprotein (a): from ancestral benefit to modern pathogen? Q J Med 2000;93:75–84.10.1093/qjmed/93.2.75Search in Google Scholar PubMed
24. Sur, D, Chakravorty, R. Association of coronary heart disease risk and lipid profile in Indian women with polycystic ovary syndrome. J Clin Gynecol Obstet 2016;5:23–6.10.14740/jcgo375wSearch in Google Scholar
25. Kelly, CJ, Lyall, H, Petrie, JR, Gould, GW, Connell, JM, Rumley, A, et al.. A specific elevation in tissue plasminogen activator antigen in women with polycystic ovarian syndrome. J Clin Endocrinol Metabol 2002;87:3287–90.10.1210/jcem.87.7.8634Search in Google Scholar PubMed
26. Carmassi, F, De Negri, F, Fioriti, R, De Giorgi, A, Giannarelli, C, Fruzzetti, F, et al.. Insulin resistance causes impaired vasodilation and hypofibrinolysis in young women with polycystic ovary syndrome. Thromb Res 2005;116:207–14.10.1016/j.thromres.2004.11.026Search in Google Scholar PubMed
27. Wood, JR, Nelson, VL, Ho, C, Jansen, E, Wang, CY, Urbanek, M, et al.. The molecular phenotype of polycystic ovary syndrome (PCOS) theca cells and new candidate PCOS genes defined by microarray analysis. J Biol Chem 2003;278:26380–90.10.1074/jbc.M300688200Search in Google Scholar PubMed
28. Diamanti-Kandarakis, E, Piperi, C, Argyrakopoulou, G, Spina, J, Papanastasiou, L, Bergiele, A, et al.. Polycystic ovary syndrome: the influence of environmental and genetic factors. Hormones-Athens 2006;5:17.10.14310/horm.2002.11165Search in Google Scholar PubMed
29. Rabelo-Acevedo, M, Ramírez-Vick, M. Association between the polycystic ovary syndrome and the metabolic syndrome in Puerto Rico. Puert Rico Health Sci J 2005;24:203–6.10.1016/S1530-891X(20)43640-7Search in Google Scholar
30. Wang, ET, Calderon-Margalit, R, Cedars, MI, Daviglus, ML, Merkin, SS, Schreiner, PJ, et al.. Polycystic ovary syndrome and risk for long-term diabetes and dyslipidemia. Obstet Gynecol 2011;117:6–13.10.1097/AOG.0b013e31820209bbSearch in Google Scholar PubMed PubMed Central
31. Cho, LW, Randeva, HS, Atkin, SL. Cardiometabolic aspects of polycystic ovarian syndrome. Vasc Health Risk Manag 2007;3:55.Search in Google Scholar
32. Cussons, AJ, Stuckey, BG, Watts, GF. Metabolic syndrome and cardiometabolic risk in PCOS. Curr Diabetes Rep 2007;7:66–73.10.1007/s11892-007-0012-8Search in Google Scholar PubMed
33. Hoffman, LK, Ehrmann, DA. Cardiometabolic features of polycystic ovary syndrome. Nat Clin Pract Endocrinol Metabol 2008;4:215–22.10.1038/ncpendmet0755Search in Google Scholar PubMed
34. Westerveld, HE, Hoogendoorn, M, de Jong, AW, Goverde, AJ, Fauser, BC, Dallinga-Thie, GM. Cardiometabolic abnormalities in the polycystic ovary syndrome: pharmacotherapeutic insights. Pharmacol Therapeut 2008;119:223–41.10.1016/j.pharmthera.2008.04.009Search in Google Scholar PubMed
35. Rocha, MP, Marcondes, JA, Barcellos, CR, Hayashida, SA, Curi, DD, da Fonseca, AM, et al.. Dyslipidemia in women with polycystic ovary syndrome: incidence, pattern and predictors. Gynecol Endocrinol 2011;27:814–9.10.3109/09513590.2010.508852Search in Google Scholar
36. Naidu, JN, Swapna, GN, Kumar, AN, Krishnamma, M, Anitha, M. Importance of elevated insulin resistance, dyslipidemia and status of antioxidant vitamins in polycystic ovary disease. Free Radic Antioxidants 2013;3:17–9.10.1016/j.fra.2013.03.001Search in Google Scholar
37. Banu, LM, Wahab, MA, Debnath, BC, Begum, D, Arslan, MI. Characteristics of insulin and androgen status in polycystic ovary syndrome. Bangladesh J Med Biochem 2010;3:11–5.10.3329/bjmb.v3i1.13801Search in Google Scholar
38. Yilmaz, M, Biri, A, Bukan, N, Karakoç, A, Sancak, B, Törüner, F, et al.. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome. Gynecol Endocrinol 2005;20:258–63.10.1080/09513590400027265Search in Google Scholar
39. Tsouma, I, Kouskouni, E, Demeridou, S, Boutsikou, M, Hassiakos, D, Chasiakou, A, et al.. Correlation of visfatin levels and lipoprotein lipid profiles in women with polycystic ovary syndrome undergoing ovarian stimulation. Gynecol Endocrinol 2014;30:516–9.10.3109/09513590.2014.896896Search in Google Scholar
40. Güdücü, N, İşçi, H, Yiğiter, AB, Dünder, İ. C-reactive protein and lipoprotein-a as markers of coronary heart disease in polycystic ovary syndrome. J Turk Ger Gynecol Assoc 2012;13:227.10.5152/jtgga.2012.35Search in Google Scholar
41. Lindholm, A, Bixo, M, Eliasson, M, Hudecova, M, Arnadottir, R, Holte, J, et al.. Tissue plasminogen activator and plasminogen activator inhibitor 1 in obese and lean patients with polycystic ovary syndrome. Gynecol Endocrinol 2010;26:743–8.10.3109/09513590.2010.487592Search in Google Scholar
42. Orio, FJr., Palomba, S, Cascella, T, Tauchmanov, L, Nardo, LG, Di Biase, S, et al.. Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome? Reprod Biomed Online 2004;9:505–10.10.1016/S1472-6483(10)61634-3Search in Google Scholar
43. Tarkun, I, Canturk, Z, Arslan, BC, Turemen, E, Tarkun, P. The plasminogen activator system in young and lean women with polycystic ovary syndrome. Endocr J 2004;51:467–72.10.1507/endocrj.51.467Search in Google Scholar PubMed
44. Oral, B, Mermi, B, Dilek, M, Alanoğlu, G, Sütçü, R. Thrombin activatable fibrinolysis inhibitor and other hemostatic parameters in patients with polycystic ovary syndrome. Gynecol Endocrinol 2009;25:110–6.10.1080/09513590802549874Search in Google Scholar PubMed
45. Elci, E, Kaya, C, Cim, N, Yildizhan, R, Elci, GG. Evaluation of cardiac risk marker levels in obese and non-obese patients with polycystic ovaries. Gynecol Endocrinol 2017;33:43–7.10.1080/09513590.2016.1203893Search in Google Scholar PubMed
46. Sahay, S, Jain, M, Dash, D, Choubey, L, Jain, S, Singh, TB. Role of plasminogen activator inhibitor type 1 (PAI-1) in PCOS patient. Int J Reprod Contracept Obstet Gynecol 2017;6:4052–8.10.18203/2320-1770.ijrcog20174061Search in Google Scholar
© 2022 Walter de Gruyter GmbH, Berlin/Boston
Articles in the same Issue
- Frontmatter
- Letter to the Editor
- Continuing medical education in Covid-19 pandemic
- Original Articles
- Reduced irisin levels in patients with acromegaly
- Clinical investigation of lipoprotein (a) levels in type 2 diabetics for cardiovascular diseases prediction and prognosis
- Exploring the relationship between vitamin D and leptin hormones in type 2 diabetes mellitus patients from Kuwait
- Serum 25(OH) vitamin D level in Relapsing-Remitting Multiple Sclerosis and clinically isolated syndrome groups
- Hypoglycemic, hypolipidemic and hepatoprotective effects of Alpinia officinarum on nicotinamide/streptozotocin induced type II diabetic rats
- Association of obesity in T2DM with differential polymorphism of ghrelin, growth hormone secretagogue receptor-1 and telomeres maintenance genes
- Effect of different dietary fats on inflammation and glucose intolerance in high fructose and high fat fed experimental animals
- Biological reference interval of nitric oxide in health and disease
- Maternal hypothyroidism prolongs gestation period and impairs glucose tolerance in offspring of Wistar rats
- A study on serum homocysteine and oxidized LDL as markers of cardiovascular risk in patients with overt hypothyroidism
- The study of serum hsCRP, ferritin, IL-6 and plasma D-dimer in COVID-19: a retrospective study
- Swimming exercise improves SIRT1, NF-κB, and IL–1β protein levels and pancreatic tissue injury in ovariectomized diabetic rats
- Short Communications
- The second wave of COVID-19 results in outbreak of mucormycosis: diabetes and immunological perspective
- A study on lipoprotein-a and PAI-1 in women with polycystic ovary syndrome
- Review Articles
- Oxytocin, the panacea for long-COVID? a review
- COVID-19 infection in pregnancy: a review of existing knowledge
Articles in the same Issue
- Frontmatter
- Letter to the Editor
- Continuing medical education in Covid-19 pandemic
- Original Articles
- Reduced irisin levels in patients with acromegaly
- Clinical investigation of lipoprotein (a) levels in type 2 diabetics for cardiovascular diseases prediction and prognosis
- Exploring the relationship between vitamin D and leptin hormones in type 2 diabetes mellitus patients from Kuwait
- Serum 25(OH) vitamin D level in Relapsing-Remitting Multiple Sclerosis and clinically isolated syndrome groups
- Hypoglycemic, hypolipidemic and hepatoprotective effects of Alpinia officinarum on nicotinamide/streptozotocin induced type II diabetic rats
- Association of obesity in T2DM with differential polymorphism of ghrelin, growth hormone secretagogue receptor-1 and telomeres maintenance genes
- Effect of different dietary fats on inflammation and glucose intolerance in high fructose and high fat fed experimental animals
- Biological reference interval of nitric oxide in health and disease
- Maternal hypothyroidism prolongs gestation period and impairs glucose tolerance in offspring of Wistar rats
- A study on serum homocysteine and oxidized LDL as markers of cardiovascular risk in patients with overt hypothyroidism
- The study of serum hsCRP, ferritin, IL-6 and plasma D-dimer in COVID-19: a retrospective study
- Swimming exercise improves SIRT1, NF-κB, and IL–1β protein levels and pancreatic tissue injury in ovariectomized diabetic rats
- Short Communications
- The second wave of COVID-19 results in outbreak of mucormycosis: diabetes and immunological perspective
- A study on lipoprotein-a and PAI-1 in women with polycystic ovary syndrome
- Review Articles
- Oxytocin, the panacea for long-COVID? a review
- COVID-19 infection in pregnancy: a review of existing knowledge
